Evidence map›Paper›PMID 40545912›Full record

ArticleAdvanced healthcare materials2025

Antitumoral Efficacy of AuNRs-Laden ECFCs In Vitro and In Vivo: Decoding the Heat and Rays Combo Treatment in Breast Cancer and Melanoma Cells.

Cecilia Anceschi, Francesca Scavone, Paolo Armanetti, Luca Menichetti, Claudia Catarinicchia, Claudia Borri, Fulvio Ratto, Filippo Micheletti, Noemi Formica, Jessica Ruzzolini and 17 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Cecilia AnceschiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Francesca ScavoneDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Paolo ArmanettiInstitute of Clinical Physiology (IFC), National Research Council, Pisa, 56124, Italy.
Luca MenichettiInstitute of Clinical Physiology (IFC), National Research Council, Pisa, 56124, Italy.
Claudia CatarinicchiaInstitute of Clinical Physiology (IFC), National Research Council, Pisa, 56124, Italy.
Claudia BorriInstitute of Applied Physics "N. Carrara" National Research Council, Sesto Fiorentino, 50019, Italy.
Fulvio RattoInstitute of Applied Physics "N. Carrara" National Research Council, Sesto Fiorentino, 50019, Italy.
Filippo MichelettiInstitute of Applied Physics "N. Carrara" National Research Council, Sesto Fiorentino, 50019, Italy.
Noemi FormicaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Jessica RuzzoliniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Elena FredianiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Anastasia ChillàDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Francesca MargheriDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Mirko SeveriDepartment of Chemistry "Ugo Schiff,", University of Florence, Sesto Fiorentino, 50019, Italy.
Rita TraversiDepartment of Chemistry "Ugo Schiff,", University of Florence, Sesto Fiorentino, 50019, Italy.
Patrizia NardiniDepartment of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, Florence, 50134, Italy.
Daniele GuastiDepartment of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, Florence, 50134, Italy.
Mario Del RossoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Tommaso Del RossoDepartment of Physics, Pontifical Catholic University of Rio de Janeiro, Rua Marquês de São Vicente 225, Gávea, Rio de Janeiro, 22451-900, Brazil.
Lisa GiovanelliDepartment of Neurosciences, Psychology, Drug, and Child Health Area (NEUROFARBA), University of Florence, Viale Pieraccini 6, Florence, 50134, Italy.
Cinzia TalamontiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Monica MangoniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Isacco DesideriDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Silvia BurchielliCenter for Experimental Biomedicine, Research Area of CNR, Pisa, 50134, Italy.
Fabiola PajarDepartment of Translational Research and New Technologies, St. Chiara Hospital, University of Pisa, Via Savi, 10, Pisa, 56100, Italy.
Gabriella FibbiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.
Anna LaurenzanaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, Florence, 50134, Italy.ORCID https://orcid.org/0000-0002-8745-3808

Funding

Associazione Italiana per la Ricerca sul Cancro IG 2020 N. 24381NextGenerationEU and Ministry of Enterprises and Made, Pocarno 2022Regione Toscana, Health Bando Ricerca Salute 2018 Therminator
6 · The paper itself

Abstract

Radiotherapy remains a cornerstone in metastatic cancer treatment but is often hindered by tumor hypoxia and radioresistance. Gold nanorods (AuNRs) offer promise in enhancing radiotherapy through hyperthermia, yet their clinical impact is limited by poor tumor targeting. Building on the previous findings demonstrating the tumor-homing ability of Endothelial Colony Forming Cells (ECFCs) loaded with AuNRs, this study advances their use as a biologically targeted delivery system for precise radiotherapy enhancement. Using 3D in vitro tumor models and in vivo studies with nude rats, it is demonstrated that ECFCs actively home to hypoxic tumor regions, overcoming traditional nanoparticle delivery limitations. This targeted approach ensures efficient AuNR accumulation, enhancing photothermal activation and maximizing radiosensitization. In vitro, ECFC-loaded AuNRs significantly amplify radiotherapy effects, inducing ferroptosis in melanoma and inhibiting autophagy in breast cancer cells-revealing distinct tumor-specific mechanisms. Moreover, ECFC-AuNRs suppress tumor proliferation and angiogenesis, blocking vessel-like structure formation in vitro and in vivo. By integrating cellular therapy with nanotechnology, this study presents a novel strategy to counter radioresistance and improve therapeutic precision. These findings lay the foundation for a clinically viable, patient-specific approach, unlocking new possibilities in advanced cancer treatment.

Indexed as

Breast NeoplasmsEndothelial CellsGoldMelanomaNanotubesAnimalsAutophagyCell Line, TumorCell ProliferationFemaleHumansRatsRats, NudeGoldautophagybreast cancerEndothelial Colony Forming Cells (ECFCs)ferroptosisgold nanorodshyperthermiamelanomaradiotherapy

Identifiers

PMID40545912
PMCPMC12391628

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.